Bli medlem
Bli medlem

Du är här

2021-09-29

Aptahem receives Turkish patent for the protection of patent family 2

Aptahem AB (publ) announces today that the Turkish patent office has approved the patent application as the first validated country in Europe. The patent was published with the patent number TR2021/013877 T4.

The approval by the Turkish patent office provides protection for the company's lead candidate Apta-1 within the patent family 2 in Turkey until 2037. The validation phase for the other specific countries where Aptahem has applied for patent protection is ongoing, with expected more approvals to come.

CEO Mikael Lindstam comments:

"I am very pleased to receive the final approval from the first of the European countries where we have applied for patent protection. Turkey is a country with many inhabitants and where we see a large long-term business potential."

For further information:

Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
E-mail: ml@aptahem.com

About Sepsis

Sepsis is today considered a world health problem and affects 49 million people worldwide each year, of which 11 million die. In Europe alone, over 1 million people are estimated to be affected by sepsis on a yearly basis*. There is currently no specific treatment for sepsis, but instead the underlying symptoms are treated with antibiotics, fluids and oxygen.

* Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, Colombara DV, Ikuta KS, Kissoon N, Finfer S, Fleischmann-Struzek C, Machado FR, Reinhart KK, Rowan K, Seymour CW, Watson RS, West TE, Marinho F, Hay SI, Lozano R, Lopez AD, Angus DC, Murray CJL, Naghavi M. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet. 2020 Jan 18;395(10219):200-211. doi: 10.1016/S0140-6736(19)32989-7. PMID: 31954465; PMCID: PMC6970225.

About Aptahem

Aptahem AB (APTA) is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved. The company's primary pharmaceutical candidate, Apta-1, is being developed with the aim of preventing the high mortality rate caused by organ and tissue damage in sepsis patients, among others. The company possesses patent protection in strategic target markets and actively seeks business development opportunities with potential collaborators.

Författare Cision